Market OutlineThe Global Pharmaceutical Manufacturing Market is valued at USD 576.54 Billion in 2024 and is projected to ...

As one FDA initiative works to sustain the momentum of rare disease research, other events threaten to slow progress.

You cannot do science without having access to MIT, access to Harvard, access to Boston University, access to Mass General ...

Anthem Biosciences IPO Allotment: The IPO of Anthem Biosciences is now heading toward its next big step and that is ‘share ...

The Trump administration’s proposed cuts to medical research and health agencies will curtail the development of promising ...

Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to ...

DelveInsight's Type 1 Diabetes pipeline report depicts a robust space with 85+ active players working to develop 100+ ...

Texas has pledged public money to research ibogaine, hoping for FDA approval to aid veterans with PTSD and addiction.

The two collaborated on research showing that quantum computing could greatly aid the design of mRNA-based medicines and ...

Drug development is a decade-long and costly process replete with failures. If we don’t incentivize continued investments in ...

Amgen Inc. (NASDAQ:AMGN) is one of the high-margin pharma stocks to buy now. HSBC has lowered its price target on Amgen Inc.

OptimizeRx is poised for profitability by 2025 with AI-driven healthcare marketing, innovative platforms, and strong growth ...